2024
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood Cancer Journal 2024, 14: 212. PMID: 39609401, PMCID: PMC11604794, DOI: 10.1038/s41408-024-01194-5.Peer-Reviewed Original ResearchConceptsIndolent non-Hodgkin lymphomaLymphoma-specific survivalDe novo DLBCLOverall survivalIndolent lymphomaT-FLHistological transformationRelative survivalDe novo diffuse large B-cell lymphomaIndolent non-Hodgkin's lymphoma subtypesDiffuse large B-cell lymphomaReceipt of prior chemotherapyAssociated with inferior survivalLarge B-cell lymphomaMedian follow-up timeStudy of adult patientsLymphoplasmacytic lymphoma/Waldenstrom macroglobulinemiaTransformed indolent lymphomaMarginal zone lymphomaNon-Hodgkin's lymphomaB-cell lymphomaTransformed follicular lymphomaIncidence of HTPopulation-based cohort studyPopulation-based studyDistinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas
Hai L, Friedel D, Hinz F, Hoffmann D, Doubrovinskaia S, Rohdjess H, Weidenauer K, Denisova E, Scheffler G, Kessler T, Kourtesakis A, Herold-Mende C, Henegariu O, Baehring J, Dietrich J, Brors B, Wick W, Sahm F, Kaulen L. Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. Neuro-Oncology 2024, noae251. PMID: 39575767, DOI: 10.1093/neuonc/noae251.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusB cell receptorCNS lymphomaTargeted therapyEpigenetic profilesB cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPromoter region hypermethylationEBV oncogeneEBV lymphomasEBV- tumorsEPIC methylation arrayWnt/beta-catenin signalingEBV diseaseBiological subtypesUnsupervised cluster analysisInterleukin-10Promoter methylationLymphomaSyk kinase activityBrain tumorsMutational landscapeLoncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington S, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith S, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson P, Grover N, Merril M, Crombie J, Shafagati N, Sterling C, Nastoupil L, Epperla N, Ayers E. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica 2024, 110: 706-714. PMID: 39540227, PMCID: PMC11873705, DOI: 10.3324/haematol.2024.285977.Peer-Reviewed Original ResearchLOTIS-2Overall response rateOverall survivalAntibody drug conjugatesBulky diseaseComplete responseRefractory diffuse large B-cell lymphomaUS centersDiffuse large B-cell lymphomaLarge B-cell lymphomaEvaluate outcomes of patientsHigh riskResponse rateB-cell histologyR/R DLBCL patientsPre-treated patientsB-cell lymphomaOutcomes of patientsProportion of patientsRetrospective cohort studyCell of originDLBCL patientsReal-world settingsRetrospective studyReal-world analysisImpact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States
Ramdhanny A, Vaughn J, Epperla N. Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. Blood 2024, 144: 3745. DOI: 10.1182/blood-2024-211747.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T cell therapyT-cell therapyChimeric antigen receptorChimeric antigen receptor T-cell therapyPresence of B symptomsLarge B-cell lymphomaB-cell lymphomaOverall survivalFood and Drug AdministrationRelative survivalB symptomsApproval of CAR-T cell therapyAdvent of chimeric antigen receptorCentral nervous system lymphomaMultivariable flexible parametric survival modelNervous system lymphomaMedian follow-upUS Food and Drug AdministrationPopulation-based cohort studySurveillance, EpidemiologyPeriod of diagnosisUS populationPersons per yearP-value <Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Thakkar D, Hill B, Kositsky R, Tian S, Biral L, Russell V, Dave T, Love C, Roth C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, McCall C, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Gordillo C, Just B, Cohen J, Baim A, Barbello J, Cavallone E, Bachanova V, Laschen M, Teferra A, Lorcy F, Lamure S, Cartron G, Dardalhon V, Naresh K, Czader M, Reddy A, Thacker E, Parker C, Happ L, Dave S. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL. Blood 2024, 144: 3409. DOI: 10.1182/blood-2024-199758.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T-cell-related encephalopathy syndromeProgression-free survivalCAR-T therapyDiffuse large B-cell lymphoma patientsActivated B-cell typeInternational Prognostic IndexChimeric antigen receptorCAR-TCytokine release syndromeOverall survivalFavorable prognosisPrognostic scoreB cellsAssociated with worse progression-free survivalAssociated with progression-free survivalSubtype of diffuse large B-cell lymphomaHigher International Prognostic IndexInternational Prognostic Index scoreAchievement of complete remissionLarge B-cell lymphomaTumors prior to treatmentSide effectsMultiple extranodal sitesSurface markers CD19Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma
Caimi P, Huntington S, Landrette S, Gough S, Dai V, Jackson B, Yu T, Chavez J, Tannenbaum-Dvir S, Matasar M. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood 2024, 144: 6505. DOI: 10.1182/blood-2024-208356.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaB-cell non-Hodgkin lymphomaDiffuse large B-cell lymphomaStem cell transplantationPhase 1 studyCell transplantationAdvanced B-cell non-Hodgkin's lymphomaB cellsMature B-cell non-Hodgkin lymphomaXenograft models of non-Hodgkin lymphomaBCL6 expressionEastern Cooperative Oncology Group performance statusModel of non-Hodgkin lymphomaAdvanced non-Hodgkin's lymphomaAllogeneic stem cell transplantationAngioimmunoblastic T-cell lymphomaAutologous stem cell transplantationLarge B-cell lymphomaNon-Hodgkin's lymphoma casesCell line-derived xenograft modelT follicular helper cellsPatient-derived xenograft modelsStandard of care therapyHigh risk of transformationCentral nervous system involvementThe effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, 56: 187-194. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforTuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.
Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.Commentaries, Editorials and LettersPhase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.Peer-Reviewed Original ResearchCAR-T cell therapyCD19-directed CAR T-cell therapyDiffuse large B-cell lymphomaT-cell therapyB-cell lymphomaCytokine release syndromeOverall response rateLarge B-cell lymphomaR/R LBCLT cells/kgAdverse eventsAutologous CAR-T cell therapyHigh grade B-cell lymphomaBispecific T-cell engager antibodiesPrimary mediastinal B-cell lymphomaPhase 2 open-labelRecommended phase 2 doseAllogeneic stem cell transplantationGrade B-cell lymphomaMediastinal B-cell lymphomaInduce long-term remissionT-cell engager antibodiesResponse ratePhase 2 doseComplete response rateReal-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e181-e190. PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaHealthcare resource utilizationR-GemOxOverall survivalR/R settingR/R diffuse large B-cell lymphomaElderly patientsLarge B-cell lymphomaDLBCL diagnosisRates of healthcare resource utilizationCombination of rituximabMedian overall survivalR/R DLBCL patientsB-cell lymphomaStem cell transplantationReal-world survivalHealthcare resource useSample of patientsMicro AbstractRelapsed/refractory settingDLBCL patientsThird-lineSecond-lineCell transplantationPost-indexRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
Uncovering Primary Extranodal Diffuse Large B Cell Lymphoma in the Adrenal and Thyroid Glands
Li J, Balbuena-Merle R, Hrones M, Gibson C. Uncovering Primary Extranodal Diffuse Large B Cell Lymphoma in the Adrenal and Thyroid Glands. American Journal Of Case Reports 2023, 25: e942659. PMID: 38287660, PMCID: PMC10838563, DOI: 10.12659/ajcr.942659.Peer-Reviewed Original ResearchReal-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Treatment Patterns, Survival, Health Resource use and Costs Among Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma. Future Oncology 2023, 20: 317-328. PMID: 38050764, DOI: 10.2217/fon-2023-0191.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaReal-world treatment patternsLarge B-cell lymphomaB-cell lymphomaTreatment patternsMedicare beneficiariesFirst-line treatmentFront-line treatmentHealthcare resource useHealth resource useElderly Medicare beneficiariesUnmet need existsOverall survivalR-CHOPMedicare patientsLater linesOlder adultsTreatmentPatientsLymphomaNeed existsSurvivalTwo-thirdsResource useSame periodMini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL
Luskin M, Shimony S, Keating J, Stock W, Hock H, Garcia J, Stahl M, Galinksy I, Leonard R, Weiner H, Flamand Y, Neuberg D, Stone R, Letai A, Winer E, Konopleva M, Jain N, DeAngelo D. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. Blood 2023, 142: 2875. DOI: 10.1182/blood-2023-174269.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAcute lymphoblastic leukemiaMeasurable residual diseaseMulticolor flow cytometryAllogeneic hematopoietic stem cell transplantationCentral nervous systemComplete remissionB-ALLT-ALLOlder ptsPhiladelphia chromosome (Ph)-negative acute lymphoblastic leukemiaFollow-upDiffuse large B-cell lymphomaComplication of cardiac surgeryMRD negativityLarge B-cell lymphomaRefractory acute lymphoblastic leukemiaCentral nervous system leukemiaRelapsed ALLDiagnosed ALLChemo-resistant diseaseHigh-risk geneticsMini-hyper-CVDBCL2 inhibitor venetoclaxMedian follow-upCAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsPrediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype
Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPre-treatment biopsiesVenular endothelial cellsLarge B-cell lymphomaMemory T cellsHigh endothelial venulesT cellsB-cell lymphomaVCAM-1E-selectinICAM-1Endothelial cellsChimeric antigen receptor T-cell therapyL-selectinPre-treatment tumor biopsiesEffector memory T cellsCentral memory T cellsCAR T-cell therapyCell therapyHEV endothelial cellsInflamed lymph nodesT-cell infiltratesT cell exhaustionT-cell therapyT-cell homingThe Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas
Francis D, Dougan J, Pillsbury C, Park S, Langermann S, Koff J, Li Z, Flowers C, Porter C. The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas. Blood 2023, 142: 4367. DOI: 10.1182/blood-2023-190405.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaAggressive B-cell lymphomasGerminal center B cellsImmune responseBurkitt's lymphomaLymphoma casesDisease progressionSiglec-15Immune deficient (SCID) BALB/c miceR diffuse large B-cell lymphomaB cellsDeficient BALB/c miceLocal anti-tumour immune responseAggressive mature B-cell lymphomaAnti-tumor immune responseBALB/c miceLarge B-cell lymphomaHealthy donor PBMCsIntensive salvage regimensMost diffuse large B-cell lymphomasEvent-free survivalFirst-line treatmentRefractory hematologic malignanciesNon-Hodgkin lymphoma casesDevelopment of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors
Chen P, Raghunandan R, Müschen M, Katz S. Development of Chimeric Antigen Receptor (CAR) T Cells Targeting MET in Lymphomas and Solid Tumors. Blood 2023, 142: 6805. DOI: 10.1182/blood-2023-186161.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaChimeric antigen receptor T cellsAntigen receptor T cellsLarge B-cell lymphomaReceptor T cellsT cellsLymphoma cell linesHGF/METMET expressionOCI-Ly3CD69 expressionDLBCL cell linesCD19-CARSolid tumorsCell linesAnti-Met monoclonal antibodiesCD19 CAR T cellsNegative diffuse large B-cell lymphomaRefractory B-cell malignanciesLoss of CD19B-cell depletionActivation marker CD69Classic Hodgkin lymphomaJurkat T cellsCD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma
Noble J, Locke F, Savid-Frontera C, Jain M, Turner J, Miranda J, Madanayake T, Naderinezhad S, Corallo S, Menges M, Reid K, Robinson T. CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma. Blood 2023, 142: 3506. DOI: 10.1182/blood-2023-185074.Peer-Reviewed Original ResearchNon-durable responseProgression free survivalSurface protein expressionB-cell acute lymphoblastic leukemiaCAR-TCAR-T treatmentFlow cytometryProtein expressionFree survivalCell linesWestern blottingRefractory diffuse large B-cell lymphomaMedian expressionChimeric antigen receptor T cellsJeKo-1Associated with progression free survivalDiffuse large B-cell lymphomaPre-treatment tumor biopsiesPre-treatment tumor samplesLarge B-cell lymphomaIntron 2CAR-T failureCD19 surface expressionR/R DLBCL patientsIntron 6FRI694 Hypercalcemia And Renal Failure As Initial Presentation Of A Rare Case Of Primary Splenic Large B Cell Lymphoma
Ding N, Majumdar S. FRI694 Hypercalcemia And Renal Failure As Initial Presentation Of A Rare Case Of Primary Splenic Large B Cell Lymphoma. Journal Of The Endocrine Society 2023, 7: bvad114.462. PMCID: PMC10555323, DOI: 10.1210/jendso/bvad114.462.Peer-Reviewed Original ResearchSplenic large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaDihydroxy vitamin DRenal failureVitamin DPg/mLCell lymphomaPg/Diffuse large B-cell lymphomaR-CHOP therapyPatient underwent splenectomyBence Jones proteinuriaBone marrow biopsyPrimary splenic lymphomaNon-Hodgkin lymphomaPrimary care doctorsAbdominal painElderly patientsInitial presentationUnderwent splenectomyCalcium 1000Further workupMRI abdomenRare etiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply